Evotec often discusses "innovate" and "execute" as two separate platforms. Is that the distinction you're referring to, where "innovate" involves working with partners to develop assets for commercial markets, and "execute" is more about fee-for-service relationships?

This adds value to the collaboration. Typically, it would be based on a large upfront research payment to cover the research costs that Evotec can manage flexibly in collaboration with the partner. Essentially, Evotec's role is to help BMS build a portfolio in the neuroscience area, because BMS doesn't have internal neuroscience research. They have very experienced people with a lot of background, but they don't have labs in that area. So they work with Evotec's joint project teams to manage those budgets, manage those projects, and make decisions. Hopefully, this will result in INDs and products that will move forward into the market.

I'm curious, what makes panomics, as implemented by Evotec, unique? How does Evotec differentiate their approach to panomics from the industry's usage of the term to attract partners and customers?

Evotec is now focusing on building proprietary molecular patient databases in certain disease areas. They are collecting high-quality clinical data from very homogeneous sets of patients over time, in a carefully curated way. For instance, in the kidney disease space, they have data from over 10,000 patients. These samples are then sequenced, producing a massive amount of data.

I'm curious, what makes panomics, as implemented by Evotec, unique? How does Evotec differentiate their approach to panomics from the industry's usage of the term to attract partners and customers?

This data is key to deconvoluting human disease pathways. Evotec's precision medicine platform is based on human disease and comes directly from patients with the disease. This approach has a direct genetic link to human disease, unlike traditional approaches to drug discovery that relied on unpredictable animal models.